Cargando…

Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature

BACKGROUND: Cancer of unknown primary (CUP) is a malignant and aggressive tumor whose primary origin is still unknown despite thorough evaluation. CUP can be life-threatening with a median overall survival of less than 1 year based on empirical chemotherapy. Gene detection technology advances the dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Jin, Pan, Hongming, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154565/ https://www.ncbi.nlm.nih.gov/pubmed/37153561 http://dx.doi.org/10.3389/fimmu.2023.1181444

Ejemplares similares

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease
por: Roatt, Bruno Mendes, et al.
Publicado: (2014)

Immunohistochemical Profile for Unknown Primary Adenocarcinoma
por: Hashimoto, Kenji, et al.
Publicado: (2012)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule
por: da Silva, Danielle A. M., et al.
Publicado: (2020)

Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation
por: Yao, Jing-hao, et al.
Publicado: (2019)

Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site
por: Li, Xinrong, et al.
Publicado: (2021)

Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
por: Sheng, Jin, et al.
Publicado: (2023)

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
por: Yang, Shih-Hung, et al.
Publicado: (2022)

A case of metastatic adenocarcinoma from an unknown primary involving the aortic bifurcation
por: Safri, Lenny Suryani, et al.
Publicado: (2018)

Adenocarcinoma of Unknown Primary Site
por: Song, Seo Young, et al.
Publicado: (2002)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

“Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
por: Kolling, Stefan, et al.
Publicado: (2020)

Metastatic Melanoma with an Unknown Primary
por: Babu, Anuradha Kakkanatt, et al.
Publicado: (2022)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

Giant Spinal Intradural Metastatic Adenocarcinoma of Unknown Primary: A Rare Case Report
por: Meenakshisundaram, Natarajan, et al.
Publicado: (2019)

Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy
por: Usón Junior, Pedro Luiz Serrano, et al.
Publicado: (2019)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma
por: Feng, Jifeng, et al.
Publicado: (2023)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Metastatic Adenocarcinoma of Unknown Origin Presenting as Small Bowel Perforation: A Case Report and Literature Review
por: Alkabie, Samir, et al.
Publicado: (2015)

Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study
por: Pan, Hanbo, et al.
Publicado: (2023)

Gingival metastasis of adenocarcinoma with an unknown occult primary
por: Naik, Rashmi, et al.
Publicado: (2019)

Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
por: Huang, Shujie, et al.
Publicado: (2022)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
por: Schmitz, Christine, et al.
Publicado: (2020)

Metastatic Meningioma Presenting as Cancer of Unknown Primary
por: Gupta, Vinay, et al.
Publicado: (2013)

Metabolic phenotypes in primary unknown metastatic carcinoma
por: Kim, Hye Min, et al.
Publicado: (2014)

Right Atrial Metastatic Melanoma with Unknown Primaries
por: Kuriakose, Robin, et al.
Publicado: (2015)

Metastatic tumor of the hand of unknown primary origin
por: Giordano, Vincenzo, et al.
Publicado: (2019)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Occult Breast Cancer Presenting as Metastatic Adenocarcinoma of Unknown Primary: Clinical Presentation, Immunohistochemistry, and Molecular Analysis
por: Wang, Jue, et al.
Publicado: (2012)

Metastatic Intracranial Adenoid Cystic Carcinoma with Unknown Primary: Case Report and Review of Literature
por: Chaturvedi, Jitender, et al.
Publicado: (2017)

Metastatic osseous disease of unknown primary origin: a case report and review of literature
por: Dougherty, Alleyna, et al.
Publicado: (2023)

Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
por: Zhong, Kaihang, et al.
Publicado: (2022)

The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2022)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_16tafp1t9m74knbhn5fstunvvv